JMP Securities Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben maintains a Market Outperform rating on Spruce Biosciences (NASDAQ:SPRB) but lowers the price target from $8 to $3.

March 14, 2024 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
JMP Securities maintains a Market Outperform rating on Spruce Biosciences but lowers the price target from $8 to $3.
The reduction in price target from $8 to $3 by JMP Securities, despite maintaining a Market Outperform rating, could lead to a negative short-term sentiment among investors. This significant decrease in the price target may cause concerns about the company's future growth prospects or potential challenges it might be facing.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100